Matches in DBpedia 2016-04 for { <http://wikidata.dbpedia.org/resource/Q21098885> ?p ?o }
Showing triples 1 to 59 of
59
with 100 triples per page.
- Q21098885 subject Q7145142.
- Q21098885 subject Q7469560.
- Q21098885 subject Q8248726.
- Q21098885 subject Q8661590.
- Q21098885 subject Q8758634.
- Q21098885 subject Q8918235.
- Q21098885 subject Q9052323.
- Q21098885 abstract "Ralfinamide (INN) (code names NW-1029, FCE-26742A, PNU-0154339E) is a multimodal drug which is under investigation by Newron Pharmaceuticals for the treatment of neuropathic pain and other pain conditions such as post-operative dental pain.It has a relatively complex pharmacology, acting as a mixed voltage-gated sodium channel blocker (including Nav1.7), N-type calcium channel blocker, noncompetitive NMDA receptor antagonist, and monoamine oxidase B inhibitor.It has thus far progressed as far as phase IIb/phase III clinical trials. In 2010 it failed a phase II trial for lower back pain. Encouraging Phase II results have been announced for neuropathic pain.".
- Q21098885 atcPrefix "None".
- Q21098885 casNumber "133865-88-0".
- Q21098885 iupacName "N2-{4-[(2-Fluorobenzyl)oxy]benzyl}-L-alaninamide".
- Q21098885 pubchem "5745207".
- Q21098885 thumbnail Ralfinamide.svg?width=300.
- Q21098885 wikiPageExternalLink Default.aspx?SEZ=3&PAG=40.
- Q21098885 wikiPageWikiLink Q128406.
- Q21098885 wikiPageWikiLink Q143925.
- Q21098885 wikiPageWikiLink Q14907685.
- Q21098885 wikiPageWikiLink Q14911279.
- Q21098885 wikiPageWikiLink Q172847.
- Q21098885 wikiPageWikiLink Q18028862.
- Q21098885 wikiPageWikiLink Q198473.
- Q21098885 wikiPageWikiLink Q204711.
- Q21098885 wikiPageWikiLink Q21098995.
- Q21098885 wikiPageWikiLink Q2211523.
- Q21098885 wikiPageWikiLink Q30612.
- Q21098885 wikiPageWikiLink Q3297888.
- Q21098885 wikiPageWikiLink Q4044974.
- Q21098885 wikiPageWikiLink Q40821.
- Q21098885 wikiPageWikiLink Q410943.
- Q21098885 wikiPageWikiLink Q410954.
- Q21098885 wikiPageWikiLink Q420077.
- Q21098885 wikiPageWikiLink Q421700.
- Q21098885 wikiPageWikiLink Q424960.
- Q21098885 wikiPageWikiLink Q5308872.
- Q21098885 wikiPageWikiLink Q7145142.
- Q21098885 wikiPageWikiLink Q7180990.
- Q21098885 wikiPageWikiLink Q7469560.
- Q21098885 wikiPageWikiLink Q7553303.
- Q21098885 wikiPageWikiLink Q7825858.
- Q21098885 wikiPageWikiLink Q824258.
- Q21098885 wikiPageWikiLink Q8248726.
- Q21098885 wikiPageWikiLink Q8386.
- Q21098885 wikiPageWikiLink Q8661590.
- Q21098885 wikiPageWikiLink Q8758634.
- Q21098885 wikiPageWikiLink Q8918235.
- Q21098885 wikiPageWikiLink Q9052323.
- Q21098885 atcPrefix "None".
- Q21098885 casNumber "133865".
- Q21098885 iupacName "N2-{4-[oxy]benzyl}-L-alaninamide".
- Q21098885 pubchem "5745207".
- Q21098885 type ChemicalSubstance.
- Q21098885 type Drug.
- Q21098885 type ChemicalObject.
- Q21098885 type Thing.
- Q21098885 type Q8386.
- Q21098885 comment "Ralfinamide (INN) (code names NW-1029, FCE-26742A, PNU-0154339E) is a multimodal drug which is under investigation by Newron Pharmaceuticals for the treatment of neuropathic pain and other pain conditions such as post-operative dental pain.It has a relatively complex pharmacology, acting as a mixed voltage-gated sodium channel blocker (including Nav1.7), N-type calcium channel blocker, noncompetitive NMDA receptor antagonist, and monoamine oxidase B inhibitor.It has thus far progressed as far as phase IIb/phase III clinical trials. ".
- Q21098885 label "Ralfinamide".
- Q21098885 differentFrom Q408565.
- Q21098885 depiction Ralfinamide.svg.